Search clinical trials for: 131I-rituximab

Total 3407 results

Sun Yat-sen University
Fudan University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaborators

Completed

Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy (ENCORE)

Nasopharyngeal Carcinoma

China
Fudan University

Completed

Study of Cetuximab to Treat Gastric Cancer (STAGE)

Gastric Cancer

China
Fudan University

Recruiting

Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients

Squamous Cell Carcinoma of Head and Neck

China
Hoffmann-La Roche

Completed

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

Colorectal Cancer

Belgium, Spain, France, Germany, United States, United Kingdom, Italy, Australia, Poland
UNICANCER

Completed

Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC) (TIME)

Metastatic Colorectal Cancer

France
Chinese University of Hong Kong

Completed

Cetuximab Rechallenge Study

Metastatic Colorectal Cancer

Hong Kong
Eisai Inc.

Completed

A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors

Advanced Colorectal Cancer

United States, Canada
Spanish Cooperative Group for the Treatment of...
Merck Sharp & Dohme LLC

Terminated

Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.

Metastatic Colorectal Cancer

Spain
Pfizer

Completed

Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

Lymphoma, B-Cell

Japan
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma

Lymphoma
University of Bologna

Terminated

Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

Italy
GlaxoSmithKline

Completed

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

Lymphoma, Mantle-Cell
GlaxoSmithKline

Completed

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement

Lymphoma, Non-Hodgkin
Corixa Corporation
GlaxoSmithKline

Unknown

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United Kingdom, United States
Jiangsu HengRui Medicine Co., Ltd.

Suspended

A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults

Plaque Psoriasis

China
University of California, San Francisco

Completed

A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma

Intraocular Lymphoma | Central Nervous System Lymphoma

United States
Grupo Español de Tratamiento de Tumores de Cabeza...

Completed

TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer

Head and Neck Cancer

Spain
Cascadian Therapeutics Inc.

Completed

Phase 1 and 2 Study of PX-866 and Cetuximab

Incurable Metastatic Colorectal Carcinoma | Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

United States, Canada
St. Luke's-Roosevelt Hospital Center
Bristol-Myers Squibb

Terminated

A Study of the Perioperative Use of Cetuximab in Colon Cancer Patients

Colon Cancer

United States
Stealth BioTherapeutics Inc.

Completed

Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy (MMPOWER)

Mitochondrial Myopathy

United States
The First Affiliated Hospital of Zhengzhou University

Recruiting

Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer

Metastatic Colorectal Cancer

China
UNC Lineberger Comprehensive Cancer Center
Bristol-Myers Squibb

Terminated

Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC

Lung Cancer

United States
Institut Curie

Completed

Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage IB, Stage II, or Stage IIIB Cervical Cancer (CETUXICOL)

Cervical Cancer

France
Boneca Corporation

Terminated

Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer

Head and Neck Cancer

Finland
Institute of Oncology Ljubljana

Unknown

Treatment Selection According to Skin Reaction to Cetuximab

Head and Neck Cancer

Slovenia
Grupo Portugues de Estudo do Cancro do Pulmao

Unknown

Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC (Coimbra)

Carcinoma, Non-Small-Cell Lung

Portugal
Weill Medical College of Cornell University
Celgene

Completed

Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

Mantle Cell Lymphoma | Lymphoma, Mantle Cell

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia (LLC1315)

Chronic Lymphocytic Leukemia

Italy
City of Hope Medical Center
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma

Lymphoma

United States
The Lymphoma Academic Research Organisation

Terminated

BRIEF Bendamustine and Rituximab In Elderly Follicular (BRIEF)

Follicular Lymphoma

France, Belgium
Zhujiang Hospital

Recruiting

Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma

Papillary Thyroid Cancer

China
Progenics Pharmaceuticals, Inc.

Active, not recruiting

Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer | Cancer of the Prostate | Prostatic Neoplasm | Progressive mCRPC

United States, Canada
Motus Therapeutics, Inc.
Mayo Clinic

Completed

Study to Evaluate the Effects of RM-131 in Patients With Chronic Constipation

Chronic Constipation

United States
Peregrine Pharmaceuticals

Completed

Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme

Recurrent Glioblastoma Multiforme

United States
Shanghai Pulmonary Hospital, Shanghai, China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer

Limited Stage Small Cell Lung Cancer

China
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Small Lymphocytic Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular... and other conditions

United States
ANRS, Emerging Infectious Diseases

Completed

Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis (Lipiocis)

Hepatitis, Viral, Human | Carcinoma, Hepatocellular

France
Huiqiang Huang

Recruiting

Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma (RIPPLE)

Lymphoma, B-Cell

China
MedImmune LLC

Terminated

A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies (MEDI6469)

Advanced Solid Tumors | Aggressive B-cell Lymphomas

United States
National Research Center for Hematology, Russia

Unknown

Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma (BRiF)

Follicular Lymphoma

Russian Federation
Gruppo Italiano Studio Linfomi

Completed

Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders

Relapsed or Refractory Chronic Lymphoproliferative Disorders

Italy
Celldex Therapeutics

Terminated

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Advanced Head and Neck Squamous Cell Carcinoma

United States
Lund University Hospital

Completed

A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer. (ARTSCANIII)

Locally Advanced Head and Neck Cancer

Sweden
Georgetown University
Novartis

Terminated

A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors

Head and Neck Cancer | Colorectal Cancer

United States
Centre Antoine Lacassagne

Completed

Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck Cancer

Head and Neck Cancer

France
University Medical Center Groningen

Recruiting

Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid) (MIRROR)

Glioblastoma | High-grade Glioma

Netherlands
Xijing Hospital

Recruiting

A Small-sample, Real-world Study of Sintilimab Plus Bevacizumab/Cetuximab Plus XELOX Regimen for Conversion Therapy in Patients With Advanced Colorectal Cancer

Colorectal Cancer

China
National Cancer Institute, Naples

Recruiting

Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (CIFRA)

Colorectal Cancer | ADCC

Italy

3

Subscribe